ADC Therapeutics SA (NYSE:ADCT) Share Price

Company Profile

Business description
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
Contact
Route de la Corniche 3B
Biopole
Epalinges1066
CHE
T: +41 216530200
https://www.adctherapeutics.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
263

Recommended

As investors toil in complexity the obvious solution may be the right one.

Mark LaMonica, CFA | 24 July 2025

Streaming giant’s stellar results had areas of softness; currency tailwinds drive guidance raise.

Matthew Dolgin, CFA | 23 July 2025

A recent $1 billion investment in CBA by Texas based fund manager expresses concern for the outlook of the USD.

John Abernethy | 23 July 2025

Index	Last price	Change	% Change
All Ordinaries	8,934.30	45.10	-0.50%
CAC 40	7,831.04	12.76	0.16%
DAX 40	24,142.61	153.32	-0.63%
Dow JONES (US)	44,693.91	316.38	-0.70%
FTSE 100	9,104.24	34.13	-0.37%
HKSE	25,388.35	278.83	-1.09%
NASDAQ	21,057.96	37.94	0.18%
Nikkei 225	41,456.23	370.11	-0.88%
NZX 50 Index	12,853.46	48.33	0.38%
S&P 500	6,363.35	4.44	0.07%
S&P/ASX 200	8,666.90	42.50	-0.49%
SSE Composite Index	3,593.66	12.07	-0.33%